Zymeworks will earn up to $164m in clinical, regulatory and commercial milestone fees plus royalties for each bi-specific antibody developed under a new collaboration with Celgene.
Vancouver, British Columbia-based Zymeworks also received an undisclosed upfront payment and an equity investment from Celgene to use its Azymetric...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
